Ophthalmology Times10h
Unity Biotechnology releases topline results from phase 2b ASPIRE trial of UBX1325 in patients with diabetic macular edema
UBX1325 is a novel BCL-xL inhibitor designed to eliminate senescent cells in diabetic retinal blood vessels, while leaving ...
Knowridge Science Report15h
Nearly 10 million Americans at risk of vision loss caused by diabetes, Study Finds
A new study reveals a troubling trend: nearly 10 million Americans are now living with diabetic retinopathy, a complication ...